SCHEMBL6614477

SCHEMBL6614477

c1ncn(-c2cc[nH]n2)n1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 1/20 0.39
ALDH1A1 P00352 2/20 0.39
KDM4E B2RXH2 2/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
CYP2A6 P11509 1/20 0.39
CYP1A2 P05177 2/20 0.37
CYP2C9 P11712 2/20 0.37
CYP2C19 P33261 2/20 0.37
CYP2D6 P10635 1/20 0.37
MAPT P10636 3/20 0.35
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
CYP3A4 P08684 1/20 0.32
FBP1 P09467 1/20 0.32
LMNA P02545 1/20 0.32
POLB P06746 2/20 0.31
GLA P06280 1/20 0.31
HTT P42858 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31553322 0.72 PIM1 (0.40) PIM1ALDH1A1KDM4ESMN1; SMN2CYP2A6
SCHEMBL31553324 0.72 PIM1 (0.40) PIM1ALDH1A1KDM4ESMN1; SMN2CYP2A6
SCHEMBL21623963 0.72 KDM4E (0.45) PIM1ALDH1A1KDM4ESMN1; SMN2CYP2A6
SCHEMBL31556855 0.72 KDM4E (0.45) PIM1ALDH1A1KDM4ESMN1; SMN2CYP2A6
SCHEMBL5709843 0.71 KDM4E (0.39) PIM1ALDH1A1KDM4ESMN1; SMN2CYP2A6
SCHEMBL11889611 0.69 AXL (0.34) PIM1ALDH1A1KDM4ESMN1; SMN2CYP2A6
SCHEMBL4880326 0.68 NOTUM (0.44) ALDH1A1MAPTLMNAPOLBHTT
SCHEMBL7902 0.68 ALDH1A1 (0.47) ALDH1A1KDM4ESMN1; SMN2MAPTMEN1
SCHEMBL11545484 0.66 CYP1A2 (0.34) CYP1A2CYP2C9
SCHEMBL3624554 0.66 PIM1 (0.43) PIM1ALDH1A1KDM4ESMN1; SMN2CYP2A6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040220232-A1 Novel process for making 5-substituted pyrazoles PHAMACIA CORPORATION 2004-11-04 US disclosed
US-6750338-B2 5-AMINO- AND 5-THIO- SUBSTITUTED; PREPARED FROM A METHYLENEDITHIETANE INTERMEDIATE PHARMACIA CORPORATION 2004-06-15 US disclosed
EP-1131318-B1 PROCESS FOR MAKING 5-SUBSTITUTED PYRAZOLES USING DITHIETANES SEARLE LLC (US) 2004-03-24 EP disclosed
EP-1380584-A1 Process for making 5-substituted pyrazoles using dithietanes G.D. SEARLE & CO. (US) 2004-01-14 EP disclosed
US-20030135057-A1 Novel process for making 5-substituted pyrazoles PHARMACIA CORPORATION 2003-07-17 US disclosed
US-6482955-B2 ORGANOMETALLIC REAGENT REACTED WITH AN ACTIVATED CARBOXYLIC ACID TO PRODUCE A KETONE REACTED WITH CARBON DISULFIDE AND DIHALOMETHANE, FURTHER REACTING THE DITHIETANE PRODUCT WITH A SECONDARY AMINE, AND CONDENSING THE THIOAMIDE WITH HYDRAZINE PHARMACIA CORPORATION 2002-11-19 US disclosed
US-20020115868-A1 Novel process for making 5-substituted pyrazoles PHARMACIA CORPORATION 2002-08-22 US disclosed
US-6342608-B1 REACTING ORGANOMETALLIC REAGENT WITH ACTIVATED CARBOXYLIC ACID TO FORM KETONE, TREATING WITH MIXTURE OF CARBON DISULFIDE AND DIHALOMETHANE TO FORM DITHIETANE, REACTING WITH HYDRAZINE DERIVATIVE TO FORM THIOL-SUBSTITUTED PYRAZOLE, ALKYLATING G.D. SEARLE & COMPANY 2002-01-29 US disclosed
EP-1131318-A1 PROCESS FOR MAKING 5-SUBSTITUTED PYRAZOLES USING DITHIETANES G.D. SEARLE & CO. (US) 2001-09-12 EP disclosed
US-6242612-B1 Process for making substituted pyrazoles G. D. SEARLE & CO. 2001-06-05 US disclosed
US-6143892-A REACTING AN ORGANOMETALLIC COMPOUND WITH AN ACTIVATED FORM OF CARBOXYLIC ACID TO FORM A KETONE, TREATING KETONE WITH A MIXTURE OF CARBON DISULFIDE AND DIHALOMETHANE, AMIDATING WITH AMINE, CONDENSING THE THIOAMIDE WITH HYDRAZINE OR DERIVATIVE G. D. SEARLE & CO. (US) 2000-11-07 US disclosed
WO-2000031072-A1 PROCESS FOR MAKING 5-SUBSTITUTED PYRAZOLES USING DITHIETANES G.D. SEARLE & CO. (US) 2000-06-02 WO disclosed
CN-1033806-C Herbicidal composition DOWELANCO (US) 1997-01-15 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040220232-A1 Novel process for making 5-substituted pyrazoles MAP3K5, MAP4K2, MAPKAPK2 PIM1 975/4885ALDH1A1 1316/4885KDM4E 2170/4885
US-20020115868-A1 Novel process for making 5-substituted pyrazoles MAP3K5, MAP4K2, MAPKAPK2 PIM1 975/4885ALDH1A1 1316/4885KDM4E 2170/4885
US-20030135057-A1 Novel process for making 5-substituted pyrazoles MAP3K5, MAP4K2, MAPKAPK2 PIM1 975/4885ALDH1A1 1316/4885KDM4E 2170/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.